LSKL, Inhibitor of Thrombospondin TSP-1 |
Catalog No.GC32728 |
트롬보스폰딘 TSP-1의 억제제인 \u200b\u200bLSKL은 잠복기 연관 단백질(LAP)-TGFβ 유래 테트라펩타이드이자 경쟁적인 TGF-β1 길항제입니다. LSKL, 트롬보스폰딘 TSP-1 억제제는 TSP-1이 LAP에 결합하는 것을 억제하고 신장 간질 섬유증 및 간 섬유증을 완화합니다. 트롬보스폰딘 TSP-1의 억제제인 \u200b\u200bLSKL은 TSP-1 매개 TGF-β1 활성의 억제를 통해 지주막하 섬유증을 억제하고, 만성 수두증의 발병을 예방하고, 지주막하 출혈(SAH) 후 장기간 신경인지 결함을 개선합니다. 트롬보스폰딘 TSP-1의 억제제인 \u200b\u200bLSKL은 혈뇌장벽을 쉽게 통과할 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 283609-79-0
Sample solution is provided at 25 µL, 10mM.
LSKL, Inhibitor of Thrombospondin (TSP-1) is a peptide derived from the latency-associated peptide, inhibits thrombospondin (TSP-1) activation of TGF-β and prevents the progression of hepatic damage and fibrosis.
LSKL peptide is able to reduce liver fibrosis by inhibiting TGF-β activation[2].
LSKL (1 mg/kg, i.p.) can easily traverse the blood brain barrier. LSKL peptide also alleviates hydrocephalus and improves long-term cognitive function following SAH. Moreover, LSKL peptide inhibits subarachnoid fibrosis after SAH. LSKL treatment significantly decreases the activation of TGF-β1 in the CSF in comparison with that in the SAH+PBS group[1]. LSKL peptide (30 mg/kg, i.p.) successfully inhibits transforming growth factor (TGF) β-Smad signal activation induced by partial hepatectomy. LSKL peptide successfully attenuates TGF-β-Smad signal activation by antagonizing TSP-1, but not by reducing TSP-1 protein expression. LSKL peptide accelerates hepatocyte proliferation after hepatectomy[3].
[1]. Liao F, et al. LSKL peptide alleviates subarachnoid fibrosis and hydrocephalus by inhibiting TSP1-mediated TGF-β1 signaling activity following subarachnoid hemorrhage in rats. Exp Ther Med. 2016 Oct;12(4):2537-2543. Epub 2016 Aug 31. [2]. Laurent MA, et al. In silico characterization of the interaction between LSKL peptide, a LAP-TGF-beta derived peptide, and ADAMTS1. Comput Biol Chem. 2016 Apr;61:155-61. [3]. Kuroki H, et al. Effect of LSKL peptide on thrombospondin 1-mediated transforming growth factor β signal activation and liver regeneration after hepatectomy in an experimental model. Br J Surg. 2015 Jun;102(7):813-25.
Average Rating: 5
(Based on Reviews and 32 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *